# Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

> **NCT04799431** · PHASE1 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Pancreatic Cancer Metastatic
- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Neoantigen Vaccine with Poly-ICLC adjuvant
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT04799431
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05-03
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799431, "Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04799431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*